6-(1-(1H-1,2,4-triazol-1-yl)butyl)-2-bromobenzo[d]thiazole | 1351957-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-(1-(1H-1,2,4-triazol-1-yl)butyl)-2-bromobenzo[d]thiazole
• 英文别名: 2-Bromo-6-[1-(1,2,4-triazol-1-yl)butyl]-1,3-benzothiazole
• CAS: 1351957-39-5
• 化学式: C₁₃H₁₃BrN₄S
• 分子量: 337.243
• InChiKey: ULLHIOXJNUMARX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  71.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• CYTOCHROME P450 INHIBITORS AND USES THEREOF
  申请人：ANGION BIOMEDICA CORP.

  公开号：US20180148438A1

  公开（公告）日：2018-05-31

  The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.

  本发明提供具有一般结构式（I）及其药用可接受衍生物的化合物，如本文中一般描述的类别和亚类别，并额外提供其药用组合物，并提供用于治疗涉及纤维化和增殖的多种疾病或症状的方法，其中抗纤维化或抗增殖活性是有益的。
• Cytochrome P450 inhibitors and uses thereof
  申请人：ANGION BIOMEDICA CORP.

  公开号：US10414760B2

  公开（公告）日：2019-09-17

  The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.

  本发明提供了具有一般结构式（I）的化合物 及其药学上可接受的衍生物，如本文所描述的一般类和亚类，此外还提供了其药物组合物以及用于治疗涉及纤维化和增殖的多种病症或疾病中任何一种的方法，其中抗纤维化或抗增殖活性是有益的。
• COMPOSITIONS AND METHODS FOR TREATING DISEASE
  申请人：OEHLEN Lambertus J.M.W.

  公开号：US20150164907A1

  公开（公告）日：2015-06-18

  Methods are provided for treating fibrotic diseases and conditions or cancer and other dysproliferative diseases by administering to a subject in need there of a therapeutically effective amount of a synergistic composition comprising a phosphatidylinositol 3-kinase inhibitor and a retinoid, optionally including a CYP26 inhibitor, wherein the therapeutically effective amount suppresses fibrosis or the growth of dysproliferative cells in vivo. Compositions comprising a combination of a phosphatidylinositol 3-kinase inhibitor and a retinoid, optionally in combination with a CYP26 inhibitor, are also described.
• COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES
  申请人：ANGION BIOMEDICA CORP.

  公开号：US20160038490A1

  公开（公告）日：2016-02-11

  Methods are provided for treating cancer and other dysproliferative diseases by administering to a subject in need there of a therapeutically effective amount of a synergistic composition comprising an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; wherein said therapeutically effective amount suppresses the growth of dysproliferative cells in vivo. Compositions comprising a combination of an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor a pharmaceutically acceptable salt or prodrug thereof are also described.
• US8513291B2
  申请人：——

  公开号：US8513291B2

  公开（公告）日：2013-08-20